Health tech firm Hyperfine's prelim Q3 revenue misses estimates

Hyperfine

15/10/2025 21:16

Overview

Hyperfine prelim Q3 2025 revenue grows 27% sequentially but misses analyst expectations

Company reports 27% decline in cash burn from Q2 2025

Strong demand for next-gen Swoop system drives revenue growth

Outlook

Company did not provide specific guidance for future quarters or full-year

Result Drivers

NEXT-GEN SWOOP DEMAND - Strong market excitement and demand for next-gen Swoop system and Optive AI software drove revenue growth

DEVICE SELLING PRICE - Effective average device selling price increased by 36% sequentially, reflecting market acceptance of next-gen Swoop system

CASH BURN REDUCTION - Cash burn decreased by 27% sequentially, indicating improved financial management

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Miss
$3.40 mln
$3.50 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Hyperfine Inc is $1.40, about 46.4% below its October 14 closing price of $2.05

Press Release: ID:nBw9nhzbha

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)